Add this topic to your myFT Digest for news straight to your inbox
Chief Vas Narasimhan looks to ‘drive more value for shareholders’ with focused deals
Richard Francis’s departure from Sandoz likely to spark speculation about its future
Former tax investigator accused of disclosing Trump’s then-lawyer details
Siddhartha Mukherjee’s Vor Biopharma raises $42m for leukaemia trials
Chief executive expects 10 ‘blockbuster’ launches by 2020
Pharma group explores routes to finance ‘curative’ treatments for once-fatal diseases
Acquisition to strengthen drugmaker’s position in radiopharmaceuticals
Thousands of positions to go as part of sweeping global cost cuts
Swiss group in drive to focus on higher-margin innovative drugs
Novartis leukaemia therapy could be available for young people within weeks
Drugmaker to invest SFr90m in new production facilities
Sales growth and drug approvals accelerate in world’s second-largest market
Big pharma faces choice of whether or not to embrace revolutionary tech start-ups
The US needs a health secretary with the mettle to enact painful industry reforms
It makes no sense to rush a sale of consumer unit before pharma business strengthens
Chairman weighs spinning off consumer division after pressure from investors
The shift towards finding new treatments is a worthy gamble
Swiss pharma group’s move comes amid Trump criticism of rising costs in sector
Swiss pharmaceutical company sought ‘access to key policymakers’ after 2016 election
Hit film about smuggling of generic drugs adds to pressure on multinationals
Foresight has not been the Swiss drug manufacturer’s forte
Swiss drugmaker’s new chief Vas Narasimhan refocuses on core medicines
In-house lawyers face tough choices in the Trump era
Discordant notes expected at this year’s Asco, a kind of rock festival for pharma
International Edition